secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2023-04-07T23:59:59+00:00
Accession:  0001493152-23-011560
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech funds immune monitoring study & hires consultant for pancreatic cancer Ampligen trial
--------------------------------------------------------------------------------

- Entered $200K grant with Erasmus MC for immune monitoring in pancreatic cancer patients.
- Hired Dr. Casper H.J. van Eijck as consultant to recruit European sites for Ampligen pancreatic cancer trials.
- Consultant to also introduce COVID, Long COVID & pancreatic cancer studies into Poland.
- Consulting fee: up to $2,000/month; aggregate cap of $24,500 after AMP-270 study start.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/0001493152-23-011560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-011560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer